Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis Marco Meglio

Published Date: 07 Feb 2026

Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Boom in ADHD Coaching Has Few Rules

2.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

3.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

4.

Medicaid expansion tied to smaller declines in early-stage cancer detection

5.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot